Chiusura precedente | 4,0800 |
Aperto | 4,0600 |
Denaro | 3,9700 x 100 |
Domanda | 4,2100 x 100 |
Min-Max giorno | 4,0300 - 4,4400 |
Intervallo di 52 settimane | 1,8200 - 8,7500 |
Volume | |
Media Volume | 149.065 |
Capitalizzazione | 208,278M |
Beta (mensile su 5 anni) | 0,26 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -1,2900 |
Prossima data utili | 20 mar 2024 |
Rendimento e dividendo (futuro) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | 10,57 |
SAN JOSE, Calif., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present an abstract on RT-102 at the 2023 Annual Meeting of the American Society for Bone and Mineral Research (ASBMR) taking place on October 13-16, 2023 in Vancouver, British Columbia, Canada. The details of the presentation are as follows: A
- Topline results from this study are expected in early Q1 2024 - Celltrion has a right of first negotiation for RT-111 following positive Phase 1 results SAN JOSE, Calif., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the initiation of a Phase 1 clinical trial to evaluate the safety and tolerability of RT-111, an oral
- Two preclinical studies of RaniPill® HC achieved 18/20 successful drug delivery of orally administered teriparatide resulting in a cumulative 90% success rate - Rani will continue preclinical testing to confirm preliminary reliability rate and optimize device performance - Increased payload of up to 20mg enables potential delivery of 90+ additional drug candidates - SAN JOSE, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RA